DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Seasonal Influenza Vaccines - 5EU Drug Forecast and Market Analysis to 2025" report to their offering.
A quadrivalent formulation of Intanza Intradermal is anticipated to be launched in the EU, following the launch of quadrivalent Fluzone Intradermal in the US. The sales of quadrivalent Intanza Intradermal are expected to increase to $1.5m in 2025. Its growth will be driven by its improved immunogenicity in elderly patients compared to typical influenza vaccines and the increase in the size of Germany's elderly population.
Scope
- Overview of Seasonal Influenza Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in 5EU from 2015-2025.
- Analysis of the impact of key events as well the drivers and restraints affecting 5EU Seasonal Influenza Vaccines market.
Key Topics Covered:
1. List of Tables and Figures
2 Introduction
3 Disease Overview
3.1 Etiology and Pathophysiology
4 Disease Management
4.1 Seasonal Influenza Immunization Policy
5 Competitive Assessment
5.1 Overview
5.2 Product Profiles - Major Brands, Inactivated Vaccines
5.2.1 Fluzone Quadrivalent
5.2.2 Fluzone High-Dose
5.2.3 Fluzone Intradermal
5.2.4 Vaxigrip
5.2.5 Fluarix Tetra
5.2.6 Fluvirin
5.2.7 Afluria
5.2.8 Agrippal
5.3 Product Profiles - Major Brands, Inactivated Vaccines (Adjuvanted)
5.3.1 Fluad
5.4 Product Profiles - Major Brands, Live-Attenuated Vaccines
5.4.1 FluMist Quadrivalent
5.5 Product Profiles - Major Brands, Cell Cultured Vaccines
5.5.1 Flublok
5.5.2 Flucelvax
5.6 Other Seasonal Influenza Vaccines
5.6.1 Influvac
5.6.2 Minor Brands
6 Unmet Needs and Opportunity Analysis
6.1 Overview
6.2 Higher Level of Public Awareness and Positive Perception of Influenza Vaccines
6.3 Immunization Policies Targeting Children and Adolescents
6.4 Enhanced Vaccine Efficacy in High-Risk Groups
6.5 Vaccines Leveraging Innovative and Efficient Manufacturing Technologies
6.6 Improving the Cost-Effectiveness of Influenza Vaccines
6.7 Vaccines with Broader Influenza Strain Coverage
6.8 Improved Vaccine Safety Profile
7 Pipeline Assessment
7.1 Overview
7.2 Promising Vaccines in Clinical Development
7.2.1 Seasonal Influenza VLP Vaccine
7.2.2 VN-100
7.2.3 Quadrivalent Seasonal Influenza VLP Vaccine
7.3 Promising Vaccines in Early-Stage Development
7.3.1 FLU-v
7.3.2 M-001
7.3.3 TAK-850
7.3.4 VAX-2012Q
7.4 Other Vaccines in Development Outside the 7MM
8 Market Outlook
8.1 France
8.2 Germany
8.3 Italy
8.4 Spain
8.5 United Kingdom
9 Appendix
For more information about this report visit http://www.researchandmarkets.com/research/tqfws8/seasonal
